Gulf International Bank (UK)’s BioMarin Pharmaceuticals BMRN Stock Holding History

Gulf International Bank (UK)’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-11,414	Closed	-$618K	–	595
2025 Q3	$618K	Hold	11,414	–	–	0.02%	530
2025 Q2	$627K	Hold	11,414	–	–	0.02%	524
2025 Q1	$806K	Sell	11,414 -3,263	-22%	-$220K	0.03%	484
2024 Q4	$964K	Sell	14,677 -147	-1%	-$9.85K	0.02%	488
2024 Q3	$1.04M	Sell	14,824 -797	-5%	-$66.6K	0.03%	481
2024 Q2	$1.29M	Sell	15,621 -617	-4%	-$51.4K	0.03%	429
2024 Q1	$1.42M	Buy	16,238 +105	+0.7%	+$9.4K	0.04%	417
2023 Q4	$1.55M	Sell	16,133 -1,588	-9%	-$140K	0.04%	367
2023 Q3	$1.57M	Sell	17,721 -2,099	-11%	-$187K	0.04%	369
2023 Q2	$1.72M	Sell	19,820 -5,539	-22%	-$521K	0.04%	380
2023 Q1	$2.46M	Sell	25,359 -6,529	-20%	-$677K	0.05%	349
2022 Q4	$3.3M	Sell	31,888 -145	-0.5%	-$13.6K	0.06%	337
2022 Q3	$2.71M	Hold	32,033	–	–	0.05%	360
2022 Q2	$2.65M	Hold	32,033	–	–	0.05%	386
2022 Q1	$2.47M	Sell	32,033 -895	-3%	-$74.9K	0.04%	446
2021 Q4	$2.91M	Sell	32,928 -4,899	-13%	-$404K	0.04%	423
2021 Q3	$2.92M	Hold	37,827	–	–	0.04%	455
2021 Q2	$3.16M	Hold	37,827	–	–	0.04%	458
2021 Q1	$2.86M	Sell	37,827 -3,756	-9%	-$307K	0.04%	454
2020 Q4	$3.65M	Sell	41,583 -3,441	-8%	-$273K	0.05%	380
2020 Q3	$3.42M	Buy	45,024 +100	+0.2%	+$10.1K	0.05%	355
2020 Q2	$5.54M	Hold	44,924	–	–	0.08%	232
2020 Q1	$3.8M	Hold	44,924	–	–	0.07%	265
2019 Q4	$3.8M	Hold	44,924	–	–	0.06%	332
2019 Q3	$3.03M	Sell	44,924 -436	-1%	-$33.6K	0.05%	376
2019 Q2	$3.88M	Hold	45,360	–	–	0.06%	313
2019 Q1	$4.03M	Buy	45,360 +600	+1%	+$55.6K	0.07%	289
2018 Q4	$3.81M	Sell	44,760 -12,528	-22%	-$1.19M	0.08%	263
2018 Q3	$5.55M	Buy	57,288 +2,275	+4%	+$227K	0.07%	297
2018 Q2	$5.18M	Hold	55,013	–	–	0.07%	312
2018 Q1	$4.46M	Buy	55,013 +33	+0.1%	+$2.83K	0.06%	358
2017 Q4	$4.9M	Hold	54,980	–	–	0.06%	325
2017 Q3	$5.12M	Buy	54,980 +2,300	+4%	+$203K	0.07%	300
2017 Q2	$4.78M	Buy	52,680 +105	+0.2%	+$9.55K	0.07%	314
2017 Q1	$4.62M	Buy	52,575 +800	+2%	+$71.2K	0.07%	317
2016 Q4	$4.29M	Buy	51,775 +2,600	+5%	+$224K	0.07%	329
2016 Q3	$4.55M	Hold	49,175	–	–	0.07%	297
2016 Q2	$3.83M	Hold	49,175	–	–	0.06%	334
2016 Q1	$4.05M	Buy	49,175 +1,100	+2%	+$89.5K	0.07%	318
2015 Q4	$5.04M	Buy	48,075 +410	+0.9%	+$42.8K	0.09%	258
2015 Q3	$5.02M	Buy	47,665 +200	+0.4%	+$26.7K	0.09%	246
2015 Q2	$6.49M	Hold	47,465	–	–	0.11%	208
2015 Q1	$5.92M	Buy	47,465 +6,000	+14%	+$636K	0.11%	226
2014 Q4	$3.75M	Buy	41,465 +2,402	+6%	+$200K	0.07%	329
2014 Q3	$2.82M	Hold	39,063	–	–	0.05%	397
2014 Q2	$2.43M	Hold	39,063	–	–	0.04%	473
2014 Q1	$2.66M	Buy	39,063 +2,487	+7%	+$183K	0.05%	417
2013 Q4	$2.57M	Buy	+36,576	New	+$2.48M	0.05%	423

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Gulf International Bank (UK)'s BMRN Position: Q4 2025 in Review

Gulf International Bank (UK) sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 11,414 shares — an estimated $618K sold.

Gulf International Bank (UK) first reported a position in BMRN in Q4 2013 and held it in 48 quarters. The position peaked at $6.49M in Q2 2015. 539 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

Gulf International Bank (UK) reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Gulf International Bank (UK) sold 11,414 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $618K.
Gulf International Bank (UK) first reported a position in BioMarin Pharmaceuticals in Q4 2013 and held it in 48 quarters.
Gulf International Bank (UK)'s BioMarin Pharmaceuticals position peaked at $6.49M in Q2 2015.
539 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Gulf International Bank (UK)'s 13F filing for Q4 2025, filed 10 Feb 2026.